drugset / Trial / NCT00115492

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

NCT00115492

Phase 4 Completed 797 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times. Subjects will be given breathing tests and will record their breathing symptoms daily on diary cards. All study related medicines and medical examinations will be provided at no cost. The two drugs used in this study have been approved by FDA for use in patients with COPD.

Timeline

Start
2004-12
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled